Best Gastroenterology Companies in United States
The 273 best Gastroenterology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Freenome Health.
Ranked by disclosed equity funding and recent momentum, the 273 Gastroenterology companies we track across the United States have pulled in $10.2B in total disclosed funding, three of them crossing unicorn thresholds. That's real capital behind a sector where the [global market sits near $37.3B in 2025 and is forecast to reach $57.3B by 2032 at a 6.3% CAGR](https://www.biospace.com/press-releases/gastroenterology-market-projected-to-reach-usd-53-10-billion-by-2031-says-coherent-market-insights), driven by rising incidences of digestive disorders and an aging population that isn't getting younger.
But the revenue picture is where things get interesting. Across seven validated filers, median revenue lands at $4M with 45% YoY growth, and the combined pool hits $2.9B. Bausch Health Companies Inc. accounts for $2.5B of that alone, 571 times the sector median, with Madrigal Pharmaceuticals posting $311M at a staggering 127% growth rate. So when you're scanning this directory, don't let the median fool you. The gut-brain axis and psychoneurogastroenterology themes are drawing serious research attention, and recent hepatology coverage signals that specialist clinical interest isn't slowing down. I'd watch Enveda ($505M funded) and Evommune ($268M) as the names reshaping what ambition looks like in this space.
- Gastroenterology Market Projected to Reach USD 53.10 Billion by 2031,
Ranked: Best Gastroenterology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Freenome Health 🦄 Provider of a deep learning platform for detecting circulating cancer-related markers | $1.4B | 28 mo ago | 186 186 → 403 (+117%) | 2014 | Riley Ennis Co-Founder & CPO | 7 signals ▲40% M&A · Funding · IPO | — | 1 launch |
| 2 | Enveda 🦄 AI-based platform to decipher the chemistry of nature and develop new medicines 72Funding top 12%Moat top 32%Growth top 35%Market top 44% All 8 signals ▾Fundingtop 12% Moattop 32% Growthtop 35% Markettop 44% AItop 45% Talentbottom 49% Globalbottom 48% Techbottom 46% Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Moat: Unicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 72/100 | $505M | 9 mo ago | — | 2019 | Viswa Colluru Founder & CEO | — | — | — |
| 3 | NGM Biopharmaceuticals Developer of biologics for the treatment of cardio-metabolic and liver disease | $359M | 23 mo ago | 225 | 2007 | — | — | 659 patents Therapeutic antibodies and peptide drugs targeting ILT, glucagon, and GFRAL receptors | — |
| 4 | EndoGastric Solutions Endoluminal solutions for digestive diseases, restoring anatomy and improving patient outcomes | $355M | 54 mo ago | 80 | 2002 | — | — | 202 patents Surgical devices for gastro‑esophageal valve formation and tissue fastening | — |
| 5 | Denali Therapeutics Developer of therapies to treat neurodegenerative diseases | $347M | 27 mo ago | 377 377 → 582 (+54%) | 2015 | Alexander Schuth Co-Founder | 4 signals ▼64% Leadership · Regulatory · Earnings | 1,002 patents Neurodegenerative antibody therapies and enzyme‑fusion biologics for lysosomal disease treatment | — |
| 6 | Evommune Developer of therapeutic options for chronic inflammatory disorders 60Growth top 16%Funding top 18%News top 25%Tech top 47% All 10 signals ▾Growthtop 16% Fundingtop 18% Newstop 25% Techtop 47% Fin. healthtop 47% Moattop 47% Patentsbottom 47% Marketbottom 46% Innovationbottom 42% Globalbottom 39% Growth: Revenue +86% YoY · Fresh capital in last 24 mo Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $268M | 4 mo ago | 33 | 2020 | — | 15 signals ▲650% IPO · Earnings · M&A | 3 patents Small-molecule PKCθ inhibitors for immune‑modulating therapeutics | 2 launchs · 1 partnership |
| 7 | Barinthus Biotherapeutics Developer of T-cell immunotherapeutics to treat multiple diseases | $210M | 29 mo ago | — | 2016 | Adrian Hill Co-Founder | 3 signals M&A · Earnings | 33 patents Peptide vaccine nanocarriers for cancer immunotherapy and targeted drug delivery | — |
| 8 | Spyre Therapeutics Developer of monoclonal antibody therapeutics for inflammatory bowel disease | $180M | 30 mo ago | 30 | 2023 | Cameron Turtle CEO | — | — | 1 award |
| 9 | CinRx Pharma Developer of therapeutics targeting various conditions to improve clinical outcomes | $176M | 24 mo ago | 20 | 2015 | Jonathan Isaacsohn CEO & President | — | — | — |
| 10 | Evelo Biosciences Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer | $167M | 35 mo ago | 117 | 2015 | Simba Gill CEO | — | 385 patents Live bacterial therapeutics and extracellular vesicle formulations for cytokine modulation | — |
| 11 | Shattuck Labs Developer of an immunotherapy platform for oncology and other diseases | $165M | 9 mo ago | 89 89 → 57 (-36%) | 2016 | — | 3 signals ▼57% Earnings · Funding | 305 patents Bispecific immunomodulatory antibodies and TRIM7‑targeted protein therapeutics, including mRNA formats. | — |
| 12 | Ventyx Biosciences Developer of therapeutics to treat autoimmune diseases | $165M | 20 mo ago | 79 | 2018 | Raju Mohan Founder & CEO | 8 signals ▼47% M&A · Announcements · Lawsuit | 54 patents TYK2 kinase inhibitor design, synthesis, and crystalline forms for immunomodulatory therapeutics | — |
| 13 | Cour Pharma Developer of biotech nano-particles for immune diseases | $135M | 28 mo ago | 31 | 2013 | John Puisis Founder | — | — | — |
| 14 | Seres Therapeutics Developer of microbiome therapeutics to treat a wide range of diseases | $134M | 24 mo ago | 332 | 2010 | David Berry Founder | 4 signals ▼43% Leadership · Layoffs · Earnings | 274 patents Live bacterial therapeutics for gut microbiome modulation in infection and cancer treatment | — |
| 15 | Biora Therapeutics Developer of smart pills for targeted drug delivery to treat gastrointestinal diseases | $117M | 30 mo ago | 54 | 2010 | Adi Mohanty CEO | — | — | — |
| 16 | Geneoscopy Developer of non-invasive biomarker tests for colorectal cancer | $114M | 17 mo ago | 61 | 2015 | — | — | 14 patents Non‑invasive stool‑based nucleic‑acid diagnostics for IBD and colorectal cancer detection | 1 internship · 1 launch · 2 partnerships |
| 17 | Viome Life Sciences Provider of tests to prevent, treat, and cure chronic diseases, and cancer | $92M | 21 mo ago | 136 | 2016 | Momchilo Vuyisich Co-Founder & Chief Science Officer | — | — | — |
| 18 | Aclaris Therapeutics Biopharmaceutical company empowering patients through therapeutic innovation in immuno-inflammatory conditions | $82M | 18 mo ago | 180 | 2012 | — | 3 signals ▼86% Earnings | 239 patents Small-molecule kinase inhibitors for dermatologic and immune disorders | — |
| 19 | Cirius Therapeutics Developer of therapeutics to treat liver and metabolic diseases | $75M | 8 mo ago | 11 | 2015 | — | — | — | — |
| 20 | Auron Therapeutics Developer of cancer therapeutics for the treatment of blood cancer | $63M | 16 mo ago | 27 | 2018 | Kate Yen Co-Founder & CEO | — | — | — |
| 21 | Averto Medical Developer of medical devices for patients suffering from gastrointestinal diseases | $33M | 20 mo ago | 18 | 2016 | Kenton Fong Founder & CEO | — | — | — |
| 22 | Kanvas Biosciences Provider of imaging solutions for microbial research and infectious diseases 27Funding top 27%Talent top 38%Global bottom 38%Moat bottom 38% All 5 signals ▾Fundingtop 27% Talenttop 38% Globalbottom 38% Moatbottom 38% Marketbottom 27% Funding: Raised $29.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $30M | 1 mo ago | 10 | 2021 | Iwijn De Vlaminck Co-Founder | — | — | 1 expansion |
| 23 | FZata Developer of biologics for gastrointestinal disorders treatment | $29M | 13 mo ago | 6 | 2015 | — | — | 20 patents Engineered yeast therapeutics and TNF‑α binding protein/antibody biologics for pain and infection | — |
| 24 | LPOXY Therapeutics Developer of therapies for infectious disease prevention 24Funding top 42%Talent bottom 49%Global bottom 25%News bottom 18% All 4 signals ▾Fundingtop 42% Talentbottom 49% Globalbottom 25% Newsbottom 18% Funding: Raised $28.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $28M | 9 mo ago | — | 2020 | Larry Sutton President & Founder | — | — | — |
| 25 | Athos Therapeutics Developer of AI-based therapeutics for treating autoimmune diseases 35AI top 35%Funding top 36%Talent bottom 49%Moat bottom 45% All 6 signals ▾AItop 35% Fundingtop 36% Talentbottom 49% Moatbottom 45% Marketbottom 32% Globalbottom 25% AI: Product described with: ai-based, machine learning Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 2 mo ago | 18 | 2019 | Dimitrios Iliopoulos Co-founder | — | — | — |
| 26 | Ensho Therapeutics Developer of oral therapies for patients with inflammatory bowel diseases | $28M | 12 mo ago | — | 2024 | Neena Bitritto-Garg Founder & Co-CEO | — | — | — |
| 27 | Solarea Bio Innovating microbial solutions for human health, focusing on aging well 29Funding top 29%Moat top 39%Tech top 43%News top 44% All 7 signals ▾Fundingtop 29% Moattop 39% Techtop 43% Newstop 44% Talentbottom 49% Globalbottom 36% Marketbottom 29% Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $27M | 7 mo ago | 24 | 2017 | Gerardo Toledo Co-Founder & CEO | — | — | — |
| 28 | EvoEndo Developer of a medical device for un-sedated pediatric endoscopy | $21M | 22 mo ago | 17 | 2017 | Joel Friedlander Co-Founder | — | 22 patents Advanced flexible endoscopic systems with precise fluid, electrical, and steering control | — |
| 29 | Boomerang Medical Bioelectronic device technology for the treatment of autoimmune diseases | $18M | 9 mo ago | 5 | 2021 | — | — | — | 1 internship |
| 30 | CoapTech Developer of a minimally invasive method for the placement of gastrostomy feeding tubes into stomachs of… | $17M | 21 mo ago | 25 | 2016 | — | — | 42 patents Medical tube placement and verification in gastrointestinal and thoracoabdominal cavities | — |
| 31 | Rejuvenation Technologies Developer of nucleoside-modified TERT mRNA for antiaging | $15M | 13 mo ago | 12 | 2012 | Glenn Markov Co-Founder | — | — | — |
| 32 | AltrixBio Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases | $13M | 9 mo ago | 5 | 2019 | — | — | 2 patents Mucoadhesive drug delivery formulations for targeted mucosal administration | — |
| 33 | Accipiter Biosciences Developer of de novo protein therapies for complex diseases treatment | $13M | 7 mo ago | — | 2023 | Javier Castellanos Co-Founder & CTO | — | — | — |
| 34 | Jaguar Health Developing gastrointestinal products for human prescription use and animals 50Product top 14%Funding top 24%Innovation top 34%Growth top 43% All 11 signals ▾Producttop 14% Fundingtop 24% Innovationtop 34% Growthtop 43% Talentbottom 49% Marketbottom 48% Fin. healthbottom 48% Moatbottom 45% Newsbottom 41% Techbottom 33% Globalbottom 32% Product: 4 distinct product lines · Company stage: Public Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $12M | 5 mo ago | 46 46 → 35 (-24%) | 2013 | Lisa Conte Founder & CEO | 3 signals ▼88% Earnings · Announcements | — | 1 launch · 1 partnership |
| 35 | DeNovX Pharmaceutical company that provides platform products for pharmaceutical and medical nutrition uses | $10M | 15 mo ago | 7 | 2011 | Andrew Bond Co-Founder & COO | — | 12 patents Controlled crystal nucleation using surface‑energy‑modified amorphous substrates in solution | — |
| 36 | Anagram Developer of therapeutics for metabolic diseases | $8M | 1 mo ago | 20 | 2017 | Robert Gallotto President and Chief Executive Officer | — | — | — |
| 37 | Palisade Bio Developer of therapeutics for gastrointestinal complications | $7M | 5 mo ago | 12 | 2005 | Thomas Hallam CEO | 10 signals ▲67% Earnings · Funding | — | — |
| 38 | Altay Therapeutics Developer of therapeutics for chronic liver diseases and cancer | $7M | 17 mo ago | 7 | 2019 | Osman Ozes Founder & CSO | — | — | — |
| 39 | Amplified Sciences Developer of in-vitro diagnostic test for the detection of debilitating diseases across oncology and chronic… | $6M | 10 mo ago | 6 | 2016 | Vincent Jo Davisson Founder and CSO | — | — | 1 internship |
| 40 | Aplos Medical Developer of an implant to treat acid reflux disease | $5M | 9 mo ago | — | 2019 | Claude Tihon Founder & CEO | — | — | — |
| 41 | Mitotherapeutix Developer of small molecules based drug using siRNA technology for various diseases | $5M | 15 mo ago | 5 | 2014 | Robert Hemley Co-Founder & COO | — | 8 patents Targeted multivalent ligand drug delivery and epigenetic J‑protein expression inhibition | — |
| 42 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | 2019 | Andy Wardle Co-Founder & Advisor | — | — | — |
| 43 | LAPIX Developer of immunotherapies for immunological diseases | $3M | 10 mo ago | 9 | 2019 | Anas Fathallah Co-Founder & CEO | — | — | — |
| 44 | Oasis Pharmaceuticals Developer of therapeutics to treat inflammatory, fibrotic, and metabolic disorders | $2M | 13 mo ago | — | 2013 | Lidija Covic Founder & CSO | — | — | — |
| 45 | Invea Therapeutics Developer of therapeutics for inflammatory gastrointestinal and hepatobiliary disorders | $2M | 7 mo ago | 12 | 2021 | Krishnan Nandabalan Founder | — | — | — |
| 46 | SafeGuard Surgical Developer of surgical instruments | $2M | 9 mo ago | — | 2019 | Jill Kelley Co-Founder SafeGuard Surgical™️ | — | — | — |
| 47 | PharmaIN Biopharmaceutical company pioneering subcutaneous therapies for liver disease and cancer | $2M | 10 mo ago | 17 | 2001 | — | — | 142 patents Targeted peptide delivery using cationic lipids and NPRA/V1A receptor agonists | 1 job opening |
| 48 | PAVmed Developer of medical devices and biomarkers to detect various diseases | $845K | 4 mo ago | 107 | 2014 | — | 9 signals ▲29% Earnings · Capital raise · Announcements | 50 patents Minimally invasive catheter systems for fluid control and fibrous tissue division. | — |
| 49 | Endra Life Sciences Developer of ultrasound imaging technology for liver disease detection | $287K | 8 mo ago | 21 | 2007 | Francois Michelon CEO | 18 signals ▲157% Earnings · Funding · Announcements | 188 patents Thermoacoustic medical imaging probes and RF applicators for enhanced diagnostic imaging | — |
| 50 | PharmassetX Developer of a small molecule drug targeting chronic inflammatory diseases | $150K | 1 mo ago | — | 2024 | David McClure Co-Founder & COO | — | — | — |
Top 12 Gastroenterology companies in United States
#1
Public · Sacramento, California · founded 2020 · 33 employees$268Mraised▾
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
- Feb 2026Post IPO$125M
- Oct 2024Series C$115M
- Jun 2023Series B$7.5M
- Mar 2023Series B$57.5M
#2
Enveda 🦄Series D · Boulder, Colorado · founded 2019$504.8Mraised▾
AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.
- Sep 2025Series D$150M
- Feb 2025Series C—
- Nov 2024Series C$130M
- Jun 2024Series B$55M
#3
Series A · Ithaca, New York · founded 2021 · 10 employees$29.5Mraised▾
Provider of imaging solutions for microbial research and infectious diseases
- May 2026Series A$48M
- Mar 2024Series A$12.5M
- Jun 2023Seed$11.8M
#4
Series A · Torrance, California · founded 2019 · 18 employees$28Mraised▾
Developer of AI-based therapeutics for treating autoimmune diseases. The company has developed an innovative computational process based on machine learning algorithms that identify novel and safe drug/gene targets for individual patients. The product pipeline includes ATH-63, ATH-105, and ATH-120 for Ulcerative Colitis & Crohn’s Disease.
- Apr 2026Series A$10.3M
- Jan 2024Series A$7.6M
- Nov 2021Series A$20.4M
#5
Public · Austin, Texas · founded 2016 · 89 employees$165.4Mraised▾
Shattuck Labs is a developer of an immunotherapy platform for oncology and other diseases. The company has developed ARC (Agonist Redirected Checkpoints), which hinges on the development of bispecific biologics that simultaneously block candidate checkpoint molecules in cancer while also stimulating TNF superfamily costimulatory receptors on T cells and innate cells. The company claims that ARC is adaptable to most of the checkpoint targets currently in clinical development.
- Aug 2025Post IPO$103M
- Jun 2020Series C$83M
- Feb 2020Series B$25.4M
- May 2018Series B$46.6M
#6
Series A · Kalamazoo, Michigan · founded 2015 · 11 employees$75.2Mraised▾
Developer of therapeutics to treat liver and metabolic diseases. The company's lead product is MSDC-0602K, a second-generation insulin sensitizer for the treatment of NASH. It has the potential to reduce metabolic dysregulation that insulin resistance and tissue damage.
- Oct 2025Series A$800K
- Oct 2024Series A$1M
- Jul 2024Series A$1.3M
- May 2019Series A$7.5M
#7
Series B · Natick, Massachusetts · founded 2017 · 20 employees$8.2Mraised▾
Developer of therapeutics for metabolic diseases. It offers orally-delivered enzymes as therapies for malabsorption syndrome and nutrient metabolism disorders which is s caused by enzyme deficiencies or genetic mutations.
- May 2026Series B$250M
- Aug 2022Grant (prize money)$1.8M
- Jan 2018Grant (prize money)$3M
- Aug 2017Series A$8.2M
#8
Series B · Cambridge, Massachusetts · founded 2017 · 24 employees$27.3Mraised▾
Innovating microbial solutions for human health, focusing on aging well. The company rapidly innovates and delivers breakthrough solutions for unmet medical needs, particularly in aging health. They are committed to advancing health outcomes through microbial science. Their core values include integrity, scientific rigor, diversity and inclusion, tenacity, a sense of purpose, transparency, and innovation. They develop products to address dietary needs related to rheumatoid arthritis, psoriatic arthritis, and cellular aging. The company uses a rigorous process involving discovery, development, preclinical testing, and clinical trials. They aim to provide trustworthy solutions for health conditions, incorporating the highest level of scientific rigor into every aspect of their process. They are dedicated to improving collective health outcomes and providing transparent formulations.
- Nov 2025Series B$9.9M
- Aug 2024Series B$1M
- May 2023Series B$15M
- Sep 2020Series A$11.3M
#9
Public · San Francisco, California · founded 2013 · 46 employees$11.6Mraised▾
Jaguar Health is engaged in developing novel, sustainably derived gastrointestinal products for humans and animals. The company focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Canalevia is the company's lead animal prescription drug product candidate intended for the treatment of various forms of diarrhea in dogs and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes.
- Jan 2026Grant (prize money)$240K
- Sep 2025Post IPO$2.4M
- Feb 2023Post IPO—
- Jul 2022Post IPO$300K
#10
Public · Carlsbad, California · founded 2005 · 12 employees$7.3Mraised▾
Developer of therapeutics for gastrointestinal complications. The company's lead candidate GT-2108 is a microbiota-activated PDE4 inhibitor prodrug for the treatment of moderate-to-severe ulcerative colitis. Other drug is GT-1908 for fibrostenotic crohn’s disease.
- Jan 2026Post IPO$500K
- May 2024Post IPO$4M
- Dec 2022Post IPO—
- May 2022Post IPO$2.4M
#11
Public · San Francisco, California · founded 2007 · 225 employees$358.9Mraised▾
Developer of biologics for the treatment of cardio-metabolic and liver diseases. The drug candidate NGM282 is used for the treatment of bile acid-related diseases; non-alcoholic steatohepatitis. It also develops novel drug candidates for the treatment of Type 2 diabetes and obesity.
- Jul 2024Post IPO$142M
- Mar 2015Series D$106M
- Feb 2015Series D$57.5M
- Jul 2013Series C$50M
#12
Series A · Platte City, Missouri · founded 2020$28Mraised▾
Developer of therapies for infectious disease prevention. It offers an oral therapeutic, Sidiprev, which aims to prevent Clostridioides difficile infection by delivering oxygen directly to the bowel.
- Sep 2025Series A$28M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Gastroenterology coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.